President Trump’s Second Term Unleashes Sweeping Rollbacks on LGBTQ+ Healthcare and Equity

Starting on the first day of his second term, President Donald J. Trump initiated a rapid series of executive actions, departmental directives, and proposed regulations, many of which directly target or significantly impact health programs, policies, and efforts aimed at meeting the health needs of LGBTQ+ individuals, particularly transgender youth. This comprehensive overview details these developments, presenting them chronologically while providing essential context, analyzing their implications, and outlining the significant legal challenges that have emerged in response.

A Swift Policy U-Turn: Dismantling Biden-Era Protections

The administration’s initial actions signaled a dramatic reversal of the previous administration’s approach to LGBTQ+ equity. Key executive orders issued by President Biden, which had sought to prevent and combat discrimination based on gender identity or sexual orientation (Executive Order 13988) and advance equality for LGBTQI+ individuals (Executive Order 14075), were swiftly rescinded. Also targeted were orders establishing the White House Gender Policy Council (Executive Order 14020) and various directives related to diversity, equity, and inclusion (DEI) initiatives across federal agencies and in schools.

The immediate implications of these rescissions were profound. Experts warned of reduced federal oversight, diminished health programming, and fewer protective policies for LGBTQ+ individuals. Specifically, orders calling for LGBTQ+ health equity, national public health needs assessments, data collection on LGBTQ+ populations, and non-discrimination protections in healthcare and schools were dismantled. Advocates expressed concern that removing non-discrimination protections for LGBTQ+ young people in schools could exacerbate stigma and worsen mental health outcomes for an already vulnerable population.

Redefining "Sex" and Eradicating "Gender Ideology"

A cornerstone of the new administration’s policy was the Executive Order titled "Defending Women From Gender Ideology Extremism and Restoring Biological Truth to the Federal Government." Issued early in the term, this order sought to fundamentally redefine "sex" as an immutable binary biological classification, explicitly removing recognition of "gender identity" in federal operations and sex-protective laws.

The order declared, "It is the policy of the United States to recognize two sexes, male and female," and mandated the Executive Branch to "enforce all sex-protective laws to promote this reality." It defined sex as "an individual’s immutable biological classification as either male or female," asserting that "’sex’ is not a synonym for and does not include the concept of ‘gender identity’" and that gender identity "does not provide a meaningful basis for identification and cannot be recognized as a replacement for sex." Furthermore, the order introduced the term "gender ideology," defining it to include "the idea that there is a vast spectrum of genders that are disconnected from one’s sex" and "maintains that it is possible for a person to be born in the wrong sexed body."

The directive compelled the Secretary of Health and Human Services (HHS) to issue guidance expanding on these sex-based definitions within 30 days. It also instructed all federal agencies and employees to enforce laws protecting "men and women as biologically distinct sexes" in all official business, documents, and communications, using "sex" instead of "gender" in relevant policies. Agencies were ordered to "remove all statements, policies, regulations, forms, communications, or other internal and external messages that promote or otherwise inculcate gender ideology, and shall cease issuing such statements, policies, regulations, forms, communications or other messages." Federal forms were to exclude gender identity questions, and agencies were directed to "take all necessary steps, as permitted by law, to end the Federal funding of gender ideology."

This broad order had immediate and far-reaching implications. Federal health programs, many of which are designed to be inclusive of the LGBTQ+ community or account for gender identities, faced potential disruption in funding and guidance. Critics highlighted the order’s reliance on biological and social inaccuracies, warning that it could perpetuate misinformation and negatively impact transgender people’s health needs. Reports soon emerged of HIV programs and community health centers losing funding due to their inclusivity of transgender individuals, causing significant confusion and fear among healthcare providers.

The order also rescinded additional Biden-era executive orders, including the "Establishment of the White House Gender Policy Council," and directed agencies to withdraw guidance documents like "The White House Toolkit on Transgender Equality."

The War on DEI: Restricting Diversity, Equity, and Inclusion Initiatives

Complementing the redefinition of sex, the administration issued executive orders aimed at "Ending Radical and Wasteful DEI Programs and Preferencing" and "Ending Illegal Discrimination and Restoring Merit-Based Opportunity." These directives sought to severely limit diversity, equity, inclusion, and accessibility (DEIA) activities within government and among federal contractors and grantees.

Agencies were instructed to terminate all DEI, DEIA, and "environmental justice" offices and positions, as well as related "equity action plans," initiatives, programs, grants, and contracts. Agency heads were also required to provide the Office of Management and Budget (OMB) with lists of federal grantees that had received funding for DEI programs since January 20, 2021.

These actions were seen as a direct threat to efforts to reach populations with unique health needs in culturally competent ways, including programs related to LGBTQ+ health and HIV. Advocates warned that such efforts could jeopardize funding for agencies and organizations serving these communities.

Targeting Gender-Affirming Care for Youth: "Protecting Children" Executive Order

A significant focus of the administration’s new policy was the Executive Order "Protecting Children From Chemical and Surgical Mutilation." This order sought to significantly limit access to gender-affirming care (GAC) for individuals under 19 nationwide, framing such care as "chemical and surgical mutilation."

Key provisions of this order included:

• Directing agencies to rescind policies based on guidance from the World Professional Association for Transgender Health (WPATH), a leading authority on transgender healthcare.
• Mandating the HHS Secretary to conduct and publish a review of existing literature on GAC and gender dysphoria to "increase the quality of data to guide practices."
• Instructing federal departments and agencies providing research or education grants to medical institutions to "immediately take appropriate steps to ensure that institutions receiving Federal research or education grants end the chemical and surgical mutilation of children."
• Directing the HHS Secretary to use various regulatory and sub-regulatory actions (including those related to Medicare, Medicaid, the Affordable Care Act’s Section 1557, and diagnostic manuals) to end GAC for children.
• Withdrawing Biden Administration guidance on GAC, civil rights, and patient privacy, and directing new guidance to protect "whistleblowers" related to compliance with the order.
• Directing the Department of Defense Secretary to restrict GAC for children in the TRICARE program and the Office of Personnel Management Director to exclude "pediatric transgender surgeries or hormone treatments" from Federal Employee Health Benefits (FEHB) and Postal Service Health Benefits (PSHB) programs starting in Plan Year 2026.
• Instructing the Attorney General to prioritize enforcement of laws against female genital mutilation, erroneously conflating it with GAC, and to investigate providers and pharmaceutical companies for "misleading the public" about GAC side effects.
• Directing the Attorney General to draft legislation creating a "private right of action" for children and parents who have received GAC, with a lengthy statute of limitations and retroactive liability.
• Prioritizing investigations into "child-abusive practices by so-called sanctuary States that facilitate stripping custody from parents who support the healthy development of their own children."

The implications of this order, if fully implemented, were extensive. Access to GAC is widely associated with improved mental health outcomes for transgender people, and limiting it could lead to severe negative consequences. Medical professionals and LGBTQ+ advocates condemned the order for using biologically and socially inaccurate terms, perpetuating misinformation, and potentially promoting hostility, stigma, and discrimination. The conflation of GAC with female genital mutilation was particularly criticized as a dangerous misrepresentation.

Following this order, the VA announced it would phase out providing GAC, with exceptions for veterans already receiving hormone therapy or those separating from military service. The Office of Personnel Management also issued a letter to FEHB carriers stating that surgical or hormonal GAC for minors would not be covered starting in 2026.

Legal Floodgates Open: Challenging the Administration’s Agenda

The aggressive rollout of these policies immediately triggered a wave of legal challenges from LGBTQ+ advocacy groups, civil rights organizations, and concerned individuals. Courts, in several instances, acted to pause aspects of the administration’s implementation:

• February 4, 2025 (D.C. Federal Court): A lawsuit challenged the "Defending Women From Gender Ideology Extremism" order for usurping Congressional power, violating ACA Section 1557, and being unconstitutional. On February 11, a temporary restraining order (TRO) was issued, requiring the restoration of webpages, datasets, and resources needed for medical care identified by plaintiffs.
• February 4, 2025 (Maryland Federal Court): PFLAG filed a lawsuit challenging both the "Defending Women From Gender Ideology Extremism" and "Protecting Children From Chemical and Surgical Mutilation" orders as discriminatory, unlawful, and unconstitutional. On February 13, a federal judge issued a TRO preventing the federal government from withholding or conditioning funding based on providing GAC. This was later extended to a preliminary injunction on March 4th.
• February 7, 2025 (Washington Federal Court): Another federal lawsuit challenged the "Protecting Children From Chemical and Surgical Mutilation" order, leading to a TRO on February 14th preventing the conditioning of federal funds and also applying to the conflation of GAC with FGM. This TRO was extended through March 5th.
• February 19, 2025: The National Urban League, National Fair Housing Alliance, and AIDS Foundation of Chicago filed a suit challenging the "Ending Radical and Wasteful DEI Programs," "Defending Women From Gender Ideology Extremism," and "Ending Illegal Discrimination and Restoring Merit-Based Opportunity" orders, citing usurpation of Congressional power, constitutional violations, and potential harm to HIV and LGBTQ+ communities.
• February 20, 2025: Multiple LGBTQ+ healthcare and service organizations filed a similar suit challenging the same three DEI/gender ideology EOs. On June 9, 2026, a preliminary injunction was issued, blocking key provisions instructing agencies to remove materials and cease communications promoting "gender ideology," end federal funding of "gender ideology," and terminate DEI offices and positions.
• March 12, 2025 (Massachusetts District Court): Two physician-academics sued after their articles referencing transgender patients were removed from HHS’s Agency for Healthcare Research and Quality (AHRQ)’s Patient Safety Network. On May 23, the court granted a preliminary injunction requiring HHS to republish the censored content, citing likely success on First Amendment claims.
• March 2025 (Federal District Court): A class action lawsuit challenged the Bureau of Prisons’ implementation of the order. In June, a preliminary injunction was granted, blocking BOP officials from restricting hormone therapy and accommodations for transgender people.
• December 24, 2025 (Oregon Federal Court): 20 states challenged HHS Secretary Kennedy’s declaration regarding GAC for minors. In March 2026, a federal judge ruled that HHS had overstepped its authority, finding that the defendants lacked the power to unilaterally establish standards of care superseding professionally recognized ones or to exclude providers from federal healthcare programs based on GAC provision. The court granted summary judgment, vacated the declaration, and enjoined HHS from enforcing it in plaintiff states.

Despite these judicial interventions, the administration continued its efforts. The FBI, for example, posted on social media urging the public to "report tips of any hospitals, clinics, or practitioners performing these surgical procedures on children," even though pediatric GAC remains permitted in many states and is not federally prohibited.

Impact on Specific Health Programs and Data Collection

Beyond the broad executive orders, specific programs and data collection efforts faced direct policy changes:

• Ryan White HIV/AIDS Program (April 18, 2025): A letter reversed a Biden administration policy that allowed Ryan White funds to cover certain GAC services as part of whole-person care for transgender people with HIV. The new policy asserted that RWHAP funds "shall be marshaled exclusively toward evidence-based interventions proven to combat HIV, sustain viral suppression, and improve the quality of life for those living with the disease," prohibiting funding for services outside the scope of outpatient care, including "surgeries and inpatient care." This reversal was criticized for potentially making care engagement more challenging for transgender Ryan White clients, for whom GAC often facilitates connection to HIV services.
• Section 504 of the Rehabilitation Act (April 11, 2025 Notice): HHS issued a notice clarifying the non-enforceability of language in the preamble of a Biden-era final rule that suggested gender dysphoria could be covered by Section 504’s disability protections. This new interpretation could weaken protections for transgender and gender non-conforming individuals.
• SOGI Data Collection (May 20, 2025): CMS rescinded guidance that permitted state Medicaid programs to implement optional sexual orientation and gender identity (SOGI) questions on applications. The administration stated it would no longer collect this information from state Medicaid and Children’s Health Insurance Program (CHIP) agencies. This move significantly hinders efforts to document health experiences and disparities within LGBTQ+ populations, making it harder to inform policy and address care gaps.

The Administration’s "Evidence Review" and Clinical Recommendations

The Executive Order "Protecting Children From Chemical and Surgical Mutilation" mandated an "evidence review" of pediatric GAC. Published on May 15, 2025, this review concluded that the quality of evidence on the effects of GAC interventions was "low" and that evidence on harms was "sparse." However, it cited "significant risks" of medical transition, departing from the consensus of most U.S. medical associations. The review also promoted "exploratory therapy," which can include conversion therapy—a practice widely criticized and banned in many states for its ineffectiveness and potential for harm.

This review was swiftly criticized by external experts, including the American Academy of Pediatrics, for misrepresenting medical consensus. Nevertheless, HHS used it to send letters to providers, state medical boards, and health risk managers, urging them to update treatment protocols to align with the review’s findings and avoid WPATH Standards of Care.

Subsequently, on September 1, 2025, HHS issued "Clinical Practice Recommendations for the Evaluation and Treatment of Gender Dysphoria in Children and Adolescents." These non-binding recommendations echoed the review’s findings, urging providers to refuse pharmaceutical and surgical GAC for young patients, prioritizing psychosocial assessment and "exploratory therapy." Critics pointed out that these recommendations ignored the widely recognized benefits of GAC and the consensus of major U.S. medical associations.

Regulatory Push to Restrict GAC for Minors

The administration’s efforts culminated in a series of proposed rules designed to cement limitations on GAC for minors:

• ACA Essential Health Benefits (EHB) Rule (June 10, 2025 Final Rule): This rule prohibited GAC services from being covered as an Essential Health Benefit (EHB) in ACA plans starting in Plan Year 2026. It defined "sex-trait modification" as "any pharmaceutical or surgical intervention that is provided for the purpose of attempting to align an individual’s physical appearance or body with an asserted identity that differs from the individual’s sex." While plans could still cover GAC outside of EHBs, enrollees would lose cost-sharing and benefit design protections, potentially increasing out-of-pocket costs and making GAC less accessible, especially for low- and moderate-income individuals.
• Hospital Conditions of Participation (CoPs) Proposed Rule (October 1, 2025): This proposal sought to prohibit most Medicare and Medicaid enrolled hospitals from providing specified GAC for youth under 18, including puberty blockers, hormone therapy, and surgery. If finalized, this rule would apply to all patients under 18 in covered hospitals, regardless of their insurance, effectively limiting access nationwide.
• Medicaid/CHIP Coverage Proposed Rule (October 1, 2025): This proposed rule would prohibit the use of federal Medicaid or CHIP funds from covering pharmaceutical and surgical GAC for young people (under 18 for Medicaid, under 19 for CHIP). While states could use state-only funds, this would disproportionately impact lower-income families and further limit access nationwide.
• Section 504 of the Rehabilitation Act Proposed Rule (October 1, 2025): This proposal sought to amend federal regulations to clarify that the administration interprets statutory exclusions for "gender identity disorders not resulting from physical impairments" to encompass "gender dysphoria not resulting from a physical impairment," further weakening protections for transgender and gender non-conforming individuals.

Further Oversight, Investigations, and Grant Restrictions

The administration also leveraged other federal agencies to advance its agenda:

• FTC Request for Information (RFI) on GAC Claims (July 1, 2025): The Federal Trade Commission (FTC) sought public comment on "false or unsupported claims about ‘gender-affirming care’ (GAC), especially as it relates to minors," and potential consumer harms. This, coupled with subpoenas from the Department of Justice to over 20 providers for investigations related to GAC, raised concerns about a "chilling effect" on providers and the promotion of misinformation.
• Executive Order on Federal Grantmaking (August 1, 2025): This EO aimed to overhaul federal grantmaking, requiring agencies to ensure grants are "consistent with agency priorities and the national interest." It explicitly prohibited grants from being used to "fund, promote, encourage, subsidize, or facilitate" themes such as "denial by the grant recipient of the sex binary in humans or the notion that sex is a chosen or mutable characteristic." This could further restrict research and support for transgender and gender-diverse communities.
• CDC Updated Priorities Statement (August 15, 2025): The CDC updated its "about" website to include new priorities, stating that it is a "CDC priority to protect children from" GAC and that programs would "deprioritize programs that engage in these practices where permissible." It also affirmed that "a person’s sex as either male or female is unchangeable and determined by objective biology." This statement represented a significant departure from previous CDC messaging and could impact grantmaking, research, and public health messaging related to LGBTQ+ populations.
• FDA Warning Letters for Chest Binders (November 1, 2025): The FDA issued warning letters to 12 retailers and manufacturers of chest binders, deeming them "misbranded" medical devices that require registration. This action could create financial and logistical challenges, potentially limiting access for transgender and nonbinary individuals who use binders to alleviate gender dysphoria.
• Bureau of Prisons Guidance (November 15, 2025): Internal BOP guidance restricted the provision of surgical and hormonal GAC services and accommodations for inmates diagnosed with Gender Dysphoria, aligning with the broader administrative push to limit such care.

Conclusion

President Trump’s second term has seen a comprehensive and aggressive campaign to roll back LGBTQ+ protections and restrict access to gender-affirming care, particularly for minors. These actions, often framed under the banners of "biological truth" and "protecting children," have sparked widespread condemnation from medical organizations, civil rights advocates, and numerous states. While judicial challenges have provided some temporary relief and blocked certain provisions, the administration’s sustained efforts through executive orders, departmental directives, and proposed regulations signal a long-term strategy to fundamentally reshape federal policy regarding gender identity and LGBTQ+ health. The ongoing legal battles and policy implementations will continue to define the landscape of LGBTQ+ rights and healthcare access in the United States for years to come.